Completed PHASE2 INTERVENTIONAL 2-arm NCT02052427

Safety & Efficacy of Adipose-Derived Regenerative Cells in the Treatment of Chronic Myocardial Ischemia (ATHENA II) (ATHENA II)

Adipose-derived Regenerative Cells in the Treatment of Patients With Chronic Ischemic Heart Disease Not Amenable to Surgical or Interventional Revascularization II

Sponsor: Cytori Therapeutics

Conditions Myocardial Ischemia

Interventions Celution System Placebo

Updated 6 times since 2017 Last updated: Oct 26, 2016 Started: Jan 31, 2014 Primary completion: Aug 31, 2015 Completion: Oct 31, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Myocardial Ischemia, this trial is completed. The trial is conducted by Cytori Therapeutics and has accumulated 6 data snapshots since 2014. Cardiovascular trials of this type often inform treatment guidelines for long-term patient management.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Jan 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Cytori Therapeutics

Data source: Cytori Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Cleveland, United States